<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">WJG</journal-id><journal-title-group><journal-title>World Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1007-9327</issn><issn pub-type="epub">2219-2840</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30254402</article-id><article-id pub-id-type="pmc">6148424</article-id><article-id pub-id-type="other">jWJG.v24.i35.pg3974</article-id><article-id pub-id-type="doi">10.3748/wjg.v24.i35.3974</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Biomarkers for hepatocellular carcinoma: What&#x02019;s new on the horizon?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ocker</surname><given-names>Matthias</given-names></name><aff>Department of Translational Medicine Oncology, Bayer AG, Berlin 13353, Germany</aff><aff>Charit&#x000e9; University Medicine Berlin, Berlin 10117, Germany. <email>matthias.ocker@bayer.com</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Ocker M solely contributed to the manuscript.</p><p>Correspondence to: Matthias Ocker, MD, Professor, Department of Translational Medicine Oncology, Bayer AG, Muellerstrasse 178, Berlin 13353, Germany. <email>matthias.ocker@bayer.com</email></p><p>Telephone: +49-30-468194799 Fax: +49-30-468994799</p></fn></author-notes><pub-date pub-type="ppub"><day>21</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>21</day><month>9</month><year>2018</year></pub-date><volume>24</volume><issue>35</issue><fpage>3974</fpage><lpage>3979</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2018</year></date><date date-type="rev-recd"><day>29</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p>Treatment of advanced hepatocellular carcinoma remains unsatisfying and so far only prognostic biomarkers like &#x003b1;-fetoprotein have been established. No clear predictive biomarker is currently available for standard of care therapies, including targeted therapies like sorafenib. Novel therapeutic options like immune checkpoint inhibitors may pose new challenges to identification and validation of such markers. Currently, PD-L1 expression <italic>via</italic> immunohistochemistry and tumor mutational burden <italic>via</italic> next-generation sequencing are explored as predictive biomarkers for these novel treatments. Limited tissue availability due to lack of biopsies still restricts the use of tissue based approaches. Novel methods exploring circulating or cell free nucleic acids (DNA, RNA or miRNA-containing exosomes) could provide a new opportunity to establish predictive biomarkers. Epigenetic profiling and next-generation sequencing approaches from liquid biopsies are under development. Sample size, etiologic and geographical background need to be carefully addressed in such studies to achieve meaningful results that could be translated into clinical practice. Proteomics, metabolomics and molecular imaging are further emerging technologies.</p></abstract><kwd-group><kwd>Hepatocellular carcinoma</kwd><kwd>Biomarker</kwd><kwd>Next-generation sequencing</kwd><kwd>Liquid Biopsy</kwd><kwd>Functional imaging</kwd><kwd>Molecular imaging</kwd><kwd>Circulating free DNA</kwd><kwd>Circulating tumor cells</kwd><kwd>Immune checkpoint inhibitors</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> Hepatocellular carcinoma (HCC) is a heterogeneous disease with various underlying etiologies and an overall still poor prognosis. Biomarkers to identify optimal treatment for distinct patients are still lacking for HCC due to limited availability of biopsies. Novel treatment options, esp. immune checkpoint inhibitors, may need novel biomarker approaches and non-tissue based technologies might provide a solution to identify those biomarkers. In this article, the current status of biomarker identification for HCC is discussed.</p><sec><title>INTRODUCTION</title><p>Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and ranks 3<sup>rd</sup> in cancer-related deaths worldwide[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. While its incidence continues to be high in Africa and Asia, Western countries also showed increasing incidences rates in the past decades due to chronic hepatitis C virus (HCV) infection, alcohol consumption and high rates of obesity linked to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and subsequent development of chronic liver disease with cirrhosis[<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. Although, a slight improvement in global HCC mortality was recently reported, certain sub-populations and regions esp. in Western countries still have an unfavourable prognosis and risk assessment with continuous high incidence and mortality[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>]. Curative treatment options like surgical resection or orthotopic liver transplantation are only feasible in a minority of patients at early disease stages and with preserved liver function. Thus, the overall prognosis for patients with HCC remains unsatisfying, its 5 year survival being a dismal 6.9%, an incidence to mortality ratio of 0.95 and a median overall survival of only 11 mo[<xref rid="B7" ref-type="bibr">7</xref>]. For advanced stages, treatment is based on multi-kinase inhibitors like sorafenib or regorafenib, while recent data indicate that immune checkpoint inhibitors will lead to increased response rates also in this setting[<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Biomarkers are defined as characteristics that are measured as indicators of physiologic or pathologic processes or in response to various diagnostic or therapeutic procedures. The reader is referred to the recent definitions of the FDA-NIH Biomarker Working group for full definition of different biomarker types[<xref rid="B10" ref-type="bibr">10</xref>]. Various prognostic biomarkers, <italic>e.g</italic>., &#x003b1;-fetoprotein (AFP), AFP-L3 or Des-&#x003b3;-carboxyprothrombin (DCP), are currently used or under investigation for the early diagnosis and surveillance of HCC patients. Here, newer biomarkers like osteopontin, glypican-3 or high c-met expression have shown additional value, esp. when combining these parameters as was shown for osteopontin and AFP[<xref rid="B11" ref-type="bibr">11</xref>-<xref rid="B13" ref-type="bibr">13</xref>]. Yet, little progress was achieved in developing predictive biomarkers for targeted and other novel treatment options[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>]. In this article, the current status of predictive biomarkers for identification and selection of patients for novel therapies will be discussed.</p></sec><sec><title>BIOMARKERS FOR TARGETED THERAPIES</title><p>Sorafenib is the current standard of care for advanced HCC. Initial phase 2 data indicated that pretreatment levels of phosphorylated ERK (p-ERK) correlated with time to progression (TTP)[<xref rid="B16" ref-type="bibr">16</xref>], which was later confirmed by several preclinical and <italic>in vitro</italic> studies[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>]. Due to limited availability of tissue samples, this finding could not be confirmed in the registrational phase 3 study (SHARP trial)[<xref rid="B19" ref-type="bibr">19</xref>]. Instead, an extensive program investigating different biomarkers from plasma samples was initiated. Surprisingly, none of the investigated biomarkers predicted the response to sorafenib while biomarkers related to clinical performance, <italic>e.g</italic>., vascular invasion or AFP, as well as markers of angiogenesis like Ang2 or VEGF were shown to be independent predictors of survival in patients with advanced HCC[<xref rid="B20" ref-type="bibr">20</xref>] and thus need to be seen rather as prognostic biomarkers. In other smaller studies, elevated p-ERK and VEGF2 tissue levels were shown to be predictive for poor response to sorafenib treatment in a cohort of 77 advanced HCC patients[<xref rid="B21" ref-type="bibr">21</xref>]. Similarly, high p-ERK correlated to poor overall survival, but not time to progression, in another study with 44 patients[<xref rid="B22" ref-type="bibr">22</xref>]. Interestingly, also the multi-kinase inhibitor regorafenib, which was recently approved for second-line therapy of HCC, stratified patients only on clinical parameters and thus does not have a predictive biomarker available so far for HCC patients[<xref rid="B23" ref-type="bibr">23</xref>], while promising results on plasma circulating cell free DNA were obtained for patients with colorectal cancer[<xref rid="B24" ref-type="bibr">24</xref>].</p></sec><sec><title>BIOMARKERS FOR IMMUNE CHECKPOINT INHIBITORS</title><p>The recent success of immune checkpoint inhibitors in other cancer diseases also triggered various approaches in HCC. As HCC development is commonly based on chronic inflammatory liver diseases (viral hepatitis, NASH), a clear rationale to investigate this new treatment paradigm is clearly given. Initial results using anti-CTLA-4 or anti-PD-1 antibodies are encouraging and lead to accelerated approval of the anti-PD-1 antibody nivolumab for the treatment of advanced HCC[<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>]. Combination of checkpoint inhibitors seem feasible and the use of such drugs together with locoregional procedures in early disease settings might even further improve outcome of patients[<xref rid="B27" ref-type="bibr">27</xref>].</p><p>Still, a significant number of patients (&#x0003e; 60%) do not respond to these novel therapies. Biomarker-based enrichment was initially based on immunohistochemical expression of the respective checkpoint targets, but recent data from various indications suggest that this is not the strongest predictor for treatment response[<xref rid="B28" ref-type="bibr">28</xref>]. This could be due to the still tissue based scoring of target expression with an intrinsic risk for sampling error in heterogenous solid tumors[<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>] or due to the still not completely understood biology of checkpoint inhibition[<xref rid="B31" ref-type="bibr">31</xref>] as evidenced by approx. 10% of patients who do not express PD-L1 but respond to treatment[<xref rid="B32" ref-type="bibr">32</xref>].</p></sec><sec><title>LIQUID BIOPSIES</title><p>It is intriguing that many promising and potent drugs, <italic>e.g</italic>., sunitinib, everolimus, brivanib or tivantinib, failed in HCC clinical trials. Besides careful selection of patients based on clinical parameters like liver function or vessel invasion, all-comer trials are nowadays not considered appropriate and identification of specific patient subgroups based on distinct molecular subtypes is therefore urgently requested[<xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B35" ref-type="bibr">35</xref>].</p><p>In HCC, lack of biopsies and different etiologic backgrounds hampered the identification and validation of such markers for the currently available treatments. Even today, practice guidelines do not recommend taking biopsies of every patient although risk of bleeding and needle track seeding are infrequent and should not be seen as a reason against taking a diagnostic biopsy[<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>]. The latest EASL practice guidelines strongly recommend liver biopsy and blood sampling from patients participating in clinical and diagnostic trials[<xref rid="B37" ref-type="bibr">37</xref>].</p><p>Genomic profiling established distinct molecular subclasses of HCC that were also linked to specific gene mutations and clinical and histological features. Two major groups, the proliferative (chromosomal instable) and the non-proliferative (chromosomal stable) group, were defined which comprise approx. 50% of HCC cases each. Further analyses defined a stem cell/hepatoblast like and a TGF&#x003b2; related subgroup in the proliferative group, as well as a hepatocyte like and a Wnt/&#x003b2;-catenin related subgroup in the non-proliferative group[<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B38" ref-type="bibr">38</xref>]. While the overall impact of this classification is still under debate, additional common mutations and genetic alterations were described. Overall, mutations in telomerase signaling, the p53 and cell cycle control pathway as well as in Wnt/&#x003b2;-catenin signaling are commonly observed while rarer events include mutations in the Ras/PI3K/mTOR pathway, JAK/STAT signaling and other pathways[<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>]. Interestingly, no clear individual oncogenic driver has been identified in HCC so far and HCC is considered a cancer with medium to low mutational burden.</p><p>Analyzing tumor nucleic acids from other sources than tissue, <italic>i.e</italic>., from circulating tumor cells, cell free DNA/RNA or exosomes, could help to overcome the above mentioned limitations. Liquid biopsies usually detect expression levels, methylation status or mutations of distinct tumor related nucleic acids, including DNA, RNA and miRNAs originating from circulating tumor cells or being shed into the blood directly from living or dying tumor cells. While this approach is considered to reduce sampling error compared to solid tumor biopsies[<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>], there are still technical limitations to this technology. The success rate of detecting circulating tumor cells is depending on the size of the tumor and results seem highly variable, ranging from approx. 25% to 100% success rate within different populations and with different technical approaches[<xref rid="B42" ref-type="bibr">42</xref>]. Similar results were obtained for genetic analyses of circulating DNAs[<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>]. Surprisingly, also these studies seem to be underpowered when considering different etiologic and geographical background. A clear advantage of liquid biopsies is also the option of taking serial samples from a patient to detect changes during disease history and imposed by treatment[<xref rid="B45" ref-type="bibr">45</xref>].</p></sec><sec><title>PROTEOMICS, GLYCOMICS AND IMAGING</title><p>As the liver is the primary secretory and metabolizing organ of the body, the use of proteomics and glycomics (usually by liquid chromatography-mass spectrometry (LC-MS) or matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry analysis) could provide an option to identify novel biomarkers, too, without the current limitations of tissue based analyses. Several proteomic factors, <italic>e.g</italic>., CD44v9[<xref rid="B46" ref-type="bibr">46</xref>] or Hippocalcin-like 1 (HPCAL1)[<xref rid="B47" ref-type="bibr">47</xref>], including various multi-marker approaches were used as prognostic or diagnostic biomarkers for HCC or to predict recurrence[<xref rid="B48" ref-type="bibr">48</xref>-<xref rid="B52" ref-type="bibr">52</xref>]. Similarly, glycomics-based tests like GlycoCirrhoTest or analysis of N-glycans were developed as further diagnostic tools for better surveillance of patients at risk of HCC development[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B53" ref-type="bibr">53</xref>-<xref rid="B55" ref-type="bibr">55</xref>]. So far, these approaches were not used in a predictive setting in advanced HCC.</p><p>Beyond LC-MS or MALDI-TOF analysis, functional and molecular imaging represents a further technology to identify potential biomarkers for HCC. Functional imaging is using dynamic computed tomography, dynamic magnetic resonance imaging and diffusion weighted magnetic resonance imaging approaches and is now well established to detect changes in <italic>e.g</italic>., fibrosis grade or angiogenesis and for early diagnosis of HCC[<xref rid="B56" ref-type="bibr">56</xref>]. The development of novel radiotracers (beyond <sup>18</sup>F-FDG) for PET imaging could bridge the findings from proteomics and metabolomics analyses to imaging and thus add useful and important information on tissue distribution to these data. Today, molecular imaging for primary liver tumors is still limited by <italic>e.g</italic>., lack of specific tracer uptake into malignant cells[<xref rid="B57" ref-type="bibr">57</xref>].</p></sec><sec><title>CONCLUSION</title><p>Predictive biomarkers are considered key for the success of developing new drugs. The further development of emerging technologies that are not dependent on tissue will also increase our knowledge for the better treatment of patients but more homogeneous study design regarding technologies and patient characteristics need to be done to achieve meaningful sample sizes with results that can be robustly translated into clinical applications.</p></sec></body><back><fn-group><fn><p>Manuscript source: Invited manuscript</p></fn><fn><p>Specialty type: Gastroenterology and hepatology</p></fn><fn><p>Country of origin: Germany</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): B</p></fn><fn><p>Grade C (Good): C</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn fn-type="COI-statement"><p>Conflict-of-interest statement: The authors have no conflict of interest to declare.</p></fn><fn><p>Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/</p></fn><fn><p>Peer-review started: June 12, 2018</p></fn><fn><p>First decision: July 6, 2018</p></fn><fn><p>Article in press: August 1, 2018</p></fn><fn><p>P- Reviewer: Vradelis S, Yao DF S- Editor: Wang XJ L- Editor: A E- Editor: Yin SY</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njei</surname><given-names>B</given-names></name><name><surname>Rotman</surname><given-names>Y</given-names></name><name><surname>Ditah</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name></person-group><article-title>Emerging trends in hepatocellular carcinoma incidence and mortality</article-title><source>Hepatology</source><year>2015</year><volume>61</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">25142309</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, F&#x000fc;rst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Top&#x000f3;r-M&#x00105;dry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C</collab><article-title>The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><fpage>1683</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">28983565</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozakyol</surname><given-names>A</given-names></name></person-group><article-title>Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology)</article-title><source>J Gastrointest Cancer</source><year>2017</year><comment>Epub ahead of print</comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>Marietti</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Eslam</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name></person-group><article-title>Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28930295</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertuccio</surname><given-names>P</given-names></name><name><surname>Turati</surname><given-names>F</given-names></name><name><surname>Carioli</surname><given-names>G</given-names></name><name><surname>Rodriguez</surname><given-names>T</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Malvezzi</surname><given-names>M</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name></person-group><article-title>Global trends and predictions in hepatocellular carcinoma mortality</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">28336466</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>DL</given-names></name><name><surname>Thrift</surname><given-names>AP</given-names></name><name><surname>Kanwal</surname><given-names>F</given-names></name><name><surname>Davila</surname><given-names>J</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>812</fpage><lpage>820.e5</lpage><pub-id pub-id-type="pmid">27889576</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Papendorf</surname><given-names>F</given-names></name><name><surname>Bleck</surname><given-names>JS</given-names></name><name><surname>Kirchhoff</surname><given-names>T</given-names></name><name><surname>Wohlberedt</surname><given-names>T</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name><name><surname>Galanski</surname><given-names>M</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name></person-group><article-title>Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients</article-title><source>Br J Cancer</source><year>2005</year><volume>92</volume><fpage>1862</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">15870713</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Systemic Therapy for Hepatocellular Carcinoma: 2017 Update</article-title><source>Oncology</source><year>2017</year><volume>93 Suppl 1</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">29258077</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update</article-title><source>Oncology</source><year>2017</year><volume>93 Suppl 1</volume><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">29258079</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><collab>FDA-NIH Biomarker Working Group</collab><article-title>&#x0003e;BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]</article-title><year>2016</year></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte-Salles</surname><given-names>T</given-names></name><name><surname>Misra</surname><given-names>S</given-names></name><name><surname>Stepien</surname><given-names>M</given-names></name><name><surname>Plymoth</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>A</given-names></name><name><surname>Tj&#x000f8;nneland</surname><given-names>A</given-names></name><name><surname>Baglietto</surname><given-names>L</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population</article-title><source>Cancer Prev Res (Phila)</source><year>2016</year><volume>9</volume><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">27339170</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>WK</given-names></name><name><surname>Qi</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>SQ</given-names></name><name><surname>Fu</surname><given-names>SJ</given-names></name><name><surname>Peng</surname><given-names>BG</given-names></name><name><surname>Liang</surname><given-names>LJ</given-names></name></person-group><article-title>Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><fpage>104</fpage><pub-id pub-id-type="pmid">24548704</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Ojima</surname><given-names>H</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>J</given-names></name><name><surname>Morizane</surname><given-names>C</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma</article-title><source>Int J Clin Oncol</source><year>2013</year><volume>18</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">22218908</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>AP</given-names></name><name><surname>Mehta</surname><given-names>AS</given-names></name></person-group><article-title>The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome</article-title><source>Curr Opin Pharmacol</source><year>2018</year><volume>41</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">29772420</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Biomarkers for Hepatocellular Carcinoma</article-title><source>Biomark Cancer</source><year>2017</year><volume>9</volume><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Amadori</surname><given-names>D</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>De Greve</surname><given-names>J</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Lathia</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phase II study of sorafenib in patients with advanced hepatocellular carcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>4293</fpage><lpage>4300</lpage><pub-id pub-id-type="pmid">16908937</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Ji</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma</article-title><source>Cancer Med</source><year>2017</year><volume>6</volume><fpage>2787</fpage><lpage>2795</lpage><pub-id pub-id-type="pmid">29030911</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study</article-title><source>BMC Med</source><year>2009</year><volume>7</volume><fpage>41</fpage><pub-id pub-id-type="pmid">19698189</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>de Oliveira</surname><given-names>AC</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><collab>Llovet JM, Pe&#x000f1;a CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group</collab><article-title>Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>2290</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">22374331</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negri</surname><given-names>FV</given-names></name><name><surname>Dal Bello</surname><given-names>B</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Campanini</surname><given-names>N</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Tinelli</surname><given-names>C</given-names></name><name><surname>Poggi</surname><given-names>G</given-names></name><name><surname>Missale</surname><given-names>G</given-names></name><name><surname>Fanello</surname><given-names>S</given-names></name><name><surname>Salvagni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment</article-title><source>Liver Int</source><year>2015</year><volume>35</volume><fpage>2001</fpage><lpage>2008</lpage><pub-id pub-id-type="pmid">25559745</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Personeni</surname><given-names>N</given-names></name><name><surname>Rimassa</surname><given-names>L</given-names></name><name><surname>Pressiani</surname><given-names>T</given-names></name><name><surname>Destro</surname><given-names>A</given-names></name><name><surname>Ligorio</surname><given-names>C</given-names></name><name><surname>Tronconi</surname><given-names>MC</given-names></name><name><surname>Bozzarelli</surname><given-names>S</given-names></name><name><surname>Carnaghi</surname><given-names>C</given-names></name><name><surname>Di Tommaso</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma</article-title><source>J Cancer Res Clin Oncol</source><year>2013</year><volume>139</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">23568548</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><name><surname>Granito</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Pracht</surname><given-names>M</given-names></name><name><surname>Yokosuka</surname><given-names>O</given-names></name><name><surname>Rosmorduc</surname><given-names>O</given-names></name><name><surname>Breder</surname><given-names>V</given-names></name><etal/></person-group><article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">27932229</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AL</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Gopinathan</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>CS</given-names></name><name><surname>Soh</surname><given-names>T</given-names></name><name><surname>Venkatesh</surname><given-names>S</given-names></name><name><surname>Titin</surname><given-names>C</given-names></name><name><surname>Sapari</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib</article-title><source>J Transl Med</source><year>2015</year><volume>13</volume><fpage>57</fpage><pub-id pub-id-type="pmid">25889309</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Gomez-Martin</surname><given-names>C</given-names></name><name><surname>de la Mata</surname><given-names>M</given-names></name><name><surname>I&#x000f1;arrairaegui</surname><given-names>M</given-names></name><name><surname>Garralda</surname><given-names>E</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name><name><surname>Riezu-Boj</surname><given-names>JI</given-names></name><name><surname>Larrea</surname><given-names>E</given-names></name><name><surname>Alfaro</surname><given-names>C</given-names></name><name><surname>Sarobe</surname><given-names>P</given-names></name><etal/></person-group><article-title>A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C</article-title><source>J Hepatol</source><year>2013</year><volume>59</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23466307</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><collab>El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I</collab><article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>2492</fpage><lpage>2502</lpage><pub-id pub-id-type="pmid">28434648</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>AG</given-names></name><name><surname>Ulahannan</surname><given-names>SV</given-names></name><name><surname>Makorova-Rusher</surname><given-names>O</given-names></name><name><surname>Rahma</surname><given-names>O</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Pratt</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Heller</surname><given-names>T</given-names></name><name><surname>ElGindi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">27816492</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbone</surname><given-names>DP</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Creelan</surname><given-names>B</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Steins</surname><given-names>M</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>van den Heuvel</surname><given-names>MM</given-names></name><name><surname>Ciuleanu</surname><given-names>TE</given-names></name><name><surname>Badin</surname><given-names>F</given-names></name><etal/></person-group><article-title>First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>2415</fpage><lpage>2426</lpage><pub-id pub-id-type="pmid">28636851</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Schalper</surname><given-names>KA</given-names></name><name><surname>Carvajal-Hausdorf</surname><given-names>D</given-names></name><name><surname>Pelekanou</surname><given-names>V</given-names></name><name><surname>Rehman</surname><given-names>J</given-names></name><name><surname>Velcheti</surname><given-names>V</given-names></name><name><surname>Herbst</surname><given-names>R</given-names></name><name><surname>LoRusso</surname><given-names>P</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer</article-title><source>JAMA Oncol</source><year>2016</year><volume>2</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">26562159</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><collab>Casadevall D, Clav&#x000e9; S, Taus &#x000c1;, Hardy-Werbin M, Rocha P, Lorenzo M, Men&#x000e9;ndez S, Salido M, Albanell J, Pijuan L, Arriola E</collab><article-title>Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples</article-title><source>Clin Lung Cancer</source><year>2017</year><volume>18</volume><fpage>682</fpage><lpage>691.e5</lpage><pub-id pub-id-type="pmid">28549836</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerdes</surname><given-names>I</given-names></name><name><surname>Matikas</surname><given-names>A</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Foukakis</surname><given-names>T</given-names></name></person-group><article-title>Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>4639</fpage><lpage>4661</lpage><pub-id pub-id-type="pmid">29765155</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyriac</surname><given-names>G</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name></person-group><article-title>Emerging biomarkers for immune checkpoint inhibition in lung cancer</article-title><source>Semin Cancer Biol</source><year>2018</year></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerbes</surname><given-names>A</given-names></name><name><surname>Zoulim</surname><given-names>F</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Paradis</surname><given-names>V</given-names></name><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">29150490</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Marquardt</surname><given-names>JU</given-names></name></person-group><article-title>The role of molecular enrichment on future therapies in hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">29505843</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name></person-group><article-title>Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection</article-title><source>Liver Cancer</source><year>2016</year><volume>5</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">27493897</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimbach</surname><given-names>JK</given-names></name><name><surname>Kulik</surname><given-names>LM</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Abecassis</surname><given-names>MM</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Marrero</surname><given-names>JA</given-names></name></person-group><article-title>AASLD guidelines for the treatment of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>358</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">28130846</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><collab>European Association for the Study of the Liver</collab><article-title>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>182</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">29628281</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Lachenmayer</surname><given-names>A</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name></person-group><article-title>Advances in targeted therapies for hepatocellular carcinoma in the genomic era</article-title><source>Nat Rev Clin Oncol</source><year>2015</year><volume>12</volume><fpage>408</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">26054909</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khemlina</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>The biology of Hepatocellular carcinoma: implications for genomic and immune therapies</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><fpage>149</fpage><pub-id pub-id-type="pmid">28854942</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Li</surname><given-names>FQ</given-names></name><name><surname>Zhou</surname><given-names>XL</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>QM</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">28323123</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W</given-names></name><name><surname>Lim</surname><given-names>TK</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Phang</surname><given-names>ST</given-names></name><name><surname>Tiang</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Lim</surname><given-names>JQ</given-names></name><name><surname>Yao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>4565</fpage><pub-id pub-id-type="pmid">28240289</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okajima</surname><given-names>W</given-names></name><name><surname>Komatsu</surname><given-names>S</given-names></name><name><surname>Ichikawa</surname><given-names>D</given-names></name><name><surname>Miyamae</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>T</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Kiuchi</surname><given-names>J</given-names></name><name><surname>Nishibeppu</surname><given-names>K</given-names></name><name><surname>Arita</surname><given-names>T</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids</article-title><source>World J Gastroenterol</source><year>2017</year><volume>23</volume><fpage>5650</fpage><lpage>5668</lpage><pub-id pub-id-type="pmid">28883691</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettegowda</surname><given-names>C</given-names></name><name><surname>Sausen</surname><given-names>M</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Kinde</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luber</surname><given-names>B</given-names></name><name><surname>Alani</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Detection of circulating tumor DNA in early- and late-stage human malignancies</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><fpage>224ra24</fpage></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CKY</given-names></name><name><surname>Di Costanzo</surname><given-names>GG</given-names></name><name><surname>Terracciano</surname><given-names>LM</given-names></name><name><surname>Piscuoglio</surname><given-names>S</given-names></name></person-group><article-title>Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook</article-title><source>Front Med (Lausanne)</source><year>2018</year><volume>5</volume><fpage>78</fpage><pub-id pub-id-type="pmid">29632864</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>JCM</given-names></name><name><surname>Massie</surname><given-names>C</given-names></name><name><surname>Garcia-Corbacho</surname><given-names>J</given-names></name><name><surname>Mouliere</surname><given-names>F</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Pacey</surname><given-names>S</given-names></name><name><surname>Baird</surname><given-names>R</given-names></name><name><surname>Rosenfeld</surname><given-names>N</given-names></name></person-group><article-title>Liquid biopsies come of age: towards implementation of circulating tumour DNA</article-title><source>Nat Rev Cancer</source><year>2017</year><volume>17</volume><fpage>223</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">28233803</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakehashi</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Sugihara</surname><given-names>E</given-names></name><name><surname>Gi</surname><given-names>M</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name><name><surname>Wanibuchi</surname><given-names>H</given-names></name></person-group><article-title>CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma</article-title><source>Cancer Sci</source><year>2016</year><volume>107</volume><fpage>609</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">26882440</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>880</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">26659654</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>GS</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Tan</surname><given-names>HT</given-names></name><name><surname>Khoo</surname><given-names>ML</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Toh</surname><given-names>HC</given-names></name><name><surname>Ching Ming Chung</surname><given-names>M</given-names></name></person-group><article-title>Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients</article-title><source>J Proteome Res</source><year>2014</year><volume>13</volume><fpage>4833</fpage><lpage>4846</lpage><pub-id pub-id-type="pmid">24946162</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Tan</surname><given-names>HT</given-names></name><name><surname>Chung</surname><given-names>MC</given-names></name></person-group><article-title>Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>3112</fpage><lpage>3124</lpage><pub-id pub-id-type="pmid">24696598</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Chau</surname><given-names>GY</given-names></name><name><surname>Jan</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>CN</given-names></name><name><surname>Lin</surname><given-names>KT</given-names></name><name><surname>Juang</surname><given-names>YL</given-names></name><name><surname>Lu</surname><given-names>PJ</given-names></name><name><surname>Cheng</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma</article-title><source>Mol Cell Proteomics</source><year>2013</year><volume>12</volume><fpage>1335</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">23397142</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junrong</surname><given-names>T</given-names></name><name><surname>Huancheng</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Yi</surname><given-names>G</given-names></name><name><surname>Xiaoqin</surname><given-names>Y</given-names></name><name><surname>Zhengmao</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Jianying</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Yuanhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma</article-title><source>J Biosci</source><year>2011</year><volume>36</volume><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">21857112</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>HY</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name></person-group><article-title>NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma</article-title><source>Cancer Lett</source><year>2011</year><volume>310</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21763068</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhelst</surname><given-names>X</given-names></name><name><surname>Vanderschaeghe</surname><given-names>D</given-names></name><name><surname>Cast&#x000e9;ra</surname><given-names>L</given-names></name><name><surname>Raes</surname><given-names>T</given-names></name><name><surname>Geerts</surname><given-names>A</given-names></name><name><surname>Francoz</surname><given-names>C</given-names></name><name><surname>Colman</surname><given-names>R</given-names></name><name><surname>Durand</surname><given-names>F</given-names></name><name><surname>Callewaert</surname><given-names>N</given-names></name><name><surname>Van Vlierberghe</surname><given-names>H</given-names></name></person-group><article-title>A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><fpage>2750</fpage><lpage>2758</lpage><pub-id pub-id-type="pmid">27986746</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiyama</surname><given-names>T</given-names></name><name><surname>Yokoo</surname><given-names>H</given-names></name><name><surname>Furukawa</surname><given-names>J</given-names></name><name><surname>Kurogochi</surname><given-names>M</given-names></name><name><surname>Togashi</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Kamachi</surname><given-names>H</given-names></name><name><surname>Kakisaka</surname><given-names>T</given-names></name><name><surname>Tsuruga</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>2314</fpage><lpage>2325</lpage><pub-id pub-id-type="pmid">23322672</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>R</given-names></name><name><surname>Ressom</surname><given-names>HW</given-names></name><name><surname>Varghese</surname><given-names>RS</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name><name><surname>Bascug</surname><given-names>G</given-names></name><name><surname>Loffredo</surname><given-names>CA</given-names></name><name><surname>Abdel-Hamid</surname><given-names>M</given-names></name><name><surname>Gouda</surname><given-names>I</given-names></name><name><surname>Ezzat</surname><given-names>S</given-names></name><name><surname>Kyselova</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Detection of hepatocellular carcinoma using glycomic analysis</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1808</fpage><lpage>1813</lpage><pub-id pub-id-type="pmid">19223512</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><collab>Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, Garc&#x000ed;a-Criado &#x000c1;, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Br&#x000fa; C</collab><article-title>Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines</article-title><source>Eur J Radiol</source><year>2018</year><volume>101</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">29571804</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronot</surname><given-names>M</given-names></name><name><surname>Clift</surname><given-names>AK</given-names></name><name><surname>Vilgrain</surname><given-names>V</given-names></name><name><surname>Frilling</surname><given-names>A</given-names></name></person-group><article-title>Functional imaging in liver tumours</article-title><source>J Hepatol</source><year>2016</year><volume>65</volume><fpage>1017</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">27395013</pub-id></element-citation></ref></ref-list></back></article>